Literature DB >> 18024717

Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature.

David B Frank1, Jonathan Lowery, Lynda Anderson, Monique Brink, Jeff Reese, Mark de Caestecker.   

Abstract

Patients with familial pulmonary arterial hypertension inherit heterozygous mutations of the type 2 bone morphogenetic protein (BMP) receptor BMPR2. To explore the cellular mechanisms of this disease, we evaluated the pulmonary vascular responses to chronic hypoxia in mice carrying heterozygous hypomorphic Bmpr2 mutations (Bmpr2 delta Ex2/+). These mice develop more severe pulmonary hypertension after prolonged exposure to hypoxia without an associated increase in pulmonary vascular remodeling or proliferation compared with wild-type mice. This is associated with defective endothelial-dependent vasodilatation and enhanced vasoconstriction in isolated intrapulmonary artery preparations. In addition, there is a selective decrease in hypoxia-induced, BMP-dependent, endothelial nitric oxide synthase expression and Smad signaling in the intact lungs and in cultured pulmonary microvascular endothelial cells from Bmpr2 delta Ex2/+ mutant mice. These findings indicate that the pulmonary endothelium is a target of abnormal BMP signaling in Bmpr2 delta Ex2/+ mutant mice and suggest that endothelial dysfunction contributes to their increased susceptibility to hypoxic pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024717     DOI: 10.1152/ajplung.00034.2007

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  30 in total

1.  Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia.

Authors:  Yi Jin; Thomas J Calvert; Bernadette Chen; Louis G Chicoine; Mandar Joshi; John Anthony Bauer; Yusen Liu; Leif D Nelin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-19       Impact factor: 4.733

Review 2.  BMP signaling in vascular development and disease.

Authors:  Jonathan W Lowery; Mark P de Caestecker
Journal:  Cytokine Growth Factor Rev       Date:  2010-07-31       Impact factor: 7.638

3.  Genotype-phenotype effects of Bmpr2 mutations on disease severity in mouse models of pulmonary hypertension.

Authors:  Andrea L Frump; Arunima Datta; Sampa Ghose; James West; Mark P de Caestecker
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

4.  CTGF disrupts alveolarization and induces pulmonary hypertension in neonatal mice: implication in the pathogenesis of severe bronchopulmonary dysplasia.

Authors:  Shaoyi Chen; Min Rong; Astrid Platteau; Dorothy Hehre; Heather Smith; Philip Ruiz; Jeffrey Whitsett; Eduardo Bancalari; Shu Wu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-01-14       Impact factor: 5.464

5.  ID family protein expression and regulation in hypoxic pulmonary hypertension.

Authors:  Jonathan W Lowery; Andrea L Frump; Lynda Anderson; Gabriella E DiCarlo; Mark T Jones; Mark P de Caestecker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-09-29       Impact factor: 3.619

6.  Dependence of Golgi apparatus integrity on nitric oxide in vascular cells: implications in pulmonary arterial hypertension.

Authors:  Jason E Lee; Kirit Patel; Sharilyn Almodóvar; Rubin M Tuder; Sonia C Flores; Pravin B Sehgal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-07       Impact factor: 4.733

7.  Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia.

Authors:  Edward C Dempsey; Marilee J Wick; Vijaya Karoor; Erica J Barr; Dustin W Tallman; Carol A Wehling; Sandra J Walchak; Sven Laudi; Mysan Le; Masahiko Oka; Susan Majka; Carlyne D Cool; Karen A Fagan; Dwight J Klemm; Louis B Hersh; Norma P Gerard; Craig Gerard; York E Miller
Journal:  Am J Pathol       Date:  2009-03       Impact factor: 4.307

8.  A molecular mechanism for therapeutic effects of cGMP-elevating agents in pulmonary arterial hypertension.

Authors:  Raphaela Schwappacher; Ana Kilic; Baktybek Kojonazarov; Michaela Lang; Thuan Diep; Shunhui Zhuang; Thomas Gawlowski; Ralph T Schermuly; Alexander Pfeifer; Gerry R Boss; Renate B Pilz
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

Review 9.  Vascular remodeling in pulmonary hypertension.

Authors:  Larissa A Shimoda; Steven S Laurie
Journal:  J Mol Med (Berl)       Date:  2013-01-19       Impact factor: 4.599

Review 10.  Lung Circulation.

Authors:  Karthik Suresh; Larissa A Shimoda
Journal:  Compr Physiol       Date:  2016-03-15       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.